- Home
- RGLS vs LPTX Comparison
RGLS vs LPTX Comparison
Compare RGLS & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLS
- LPTX
- Stock Information
- Founded
- RGLS 2007
- LPTX 2011
- Country
- RGLS United States
- LPTX United States
- Employees
- RGLS N/A
- LPTX N/A
- Industry
- RGLS Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGLS Health Care
- LPTX Health Care
- Exchange
- RGLS Nasdaq
- LPTX Nasdaq
- Market Cap
- RGLS 102.8M
- LPTX 111.0M
- IPO Year
- RGLS 2012
- LPTX N/A
- Fundamental
- Price
- RGLS $1.62
- LPTX $2.78
- Analyst Decision
- RGLS Strong Buy
- LPTX Strong Buy
- Analyst Count
- RGLS 6
- LPTX 5
- Target Price
- RGLS $10.33
- LPTX $10.40
- AVG Volume (30 Days)
- RGLS 288.8K
- LPTX 88.3K
- Earning Date
- RGLS 08-08-2024
- LPTX 11-11-2024
- Dividend Yield
- RGLS N/A
- LPTX N/A
- EPS Growth
- RGLS N/A
- LPTX N/A
- EPS
- RGLS N/A
- LPTX N/A
- Revenue
- RGLS N/A
- LPTX N/A
- Revenue This Year
- RGLS N/A
- LPTX N/A
- Revenue Next Year
- RGLS N/A
- LPTX N/A
- P/E Ratio
- RGLS N/A
- LPTX N/A
- Revenue Growth
- RGLS N/A
- LPTX N/A
- 52 Week Low
- RGLS $1.08
- LPTX $1.24
- 52 Week High
- RGLS $3.79
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- RGLS 49.97
- LPTX 56.84
- Support Level
- RGLS $1.47
- LPTX $2.66
- Resistance Level
- RGLS $1.72
- LPTX $2.88
- Average True Range (ATR)
- RGLS 0.12
- LPTX 0.14
- MACD
- RGLS 0.00
- LPTX -0.03
- Stochastic Oscillator
- RGLS 48.00
- LPTX 36.77
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .